At least one study of kidney cancer has demonstrated the possibility of specifically inhibiting cytoplasmic SPOP while allowing nuclear SPOP to function normally45, which may be relevant for design of novel drugs against SPOP mutation (p.Q360*) pancreatic cancer. The gene discussed is SPOP; the disease is pancreatic neoplasm.